ReviewInternational journal of molecular sciences2025
Unraveling the Pathophysiology of Irritable Bowel Syndrome: Mechanisms and Insights.
Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Comparative Effects of Four Dietary Approaches on Symptom Severity and Quality of Life in Irritable Bowel Syndrome: A Randomized Controlled Trial.Digestive diseases and sciences · 2026Trial
- Pathophysiology-driven use of natural products in irritable bowel syndrome: a review.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Functional Reconstruction of the Gut Microecosystem in Gastrointestinal Motility Disorders: Roles of Probiotics, Prebiotics, Synbiotics and Postbiotics.Probiotics and antimicrobial proteins · 2026Review
- Irritable Bowel Syndrome: Contemporary Management Approaches, Limitations, and Future Directions.Cureus · 2026Review
- Gut Microbiota in Irritable Bowel Syndrome and Inflammatory Bowel Disease: Differences in Pathophysiology, Biomarkers, and Treatment Implications.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Irritable bowel syndrome with diarrhea: time to change practice?Current opinion in gastroenterology · 2026Review
- Article
- Plant-Derived Treatments for IBS: Clinical Outcomes, Mechanistic Insights, and Their Position in International Guidelines.Nutrients · 2026Review
- Rikkunshito ameliorates colonic dysfunction and hormonal imbalance in an IBS mouse model with modulation of transient receptor potential channel activity.Frontiers in pharmacology · 2026Article
- Pathogenesis and therapeutic strategies for irritable bowel syndrome: an integrated perspective from dynamic balance theory of Chinese medicine.Frontiers in medicine · 2026Review
- Network pharmacology identifies the mechanisms of action of Jianpi Yanggan Pill in treating diarrhea-predominant irritable bowel syndrome.American journal of translational research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Irritable Bowel Syndrome (IBS) is one of the most prevalent gastrointestinal disorders, affecting about 11% of the global population and exerting a substantial burden on quality of life and healthcare systems. Despite the emerging interest in this disease, its pathophysiology remains elusive, reflecting the interplay between the brain-gut axis, neuroendocrine dysregulation, immune activation, barrier dysfunction, microbial imbalance, and environmental triggers. Disruptions in the hypothalamic-pituitary-adrenal axis, impaired serotonin signaling, bile acid malabsorption, and altered intestinal permeability collectively result in the emergence of abnormal motility, visceral hypersensitivity, and chronic inflammation. The gut microbiome further modulates these processes by influencing neurotransmitter metabolism, immune responses, and epithelial integrity, positioning it as both a driver of symptoms and a promising therapeutic target. The aim of this review is to synthesize current mechanistic insights into IBS, highlighting the interconnected roles of the brain-gut axis, immune modulation, and microbial dynamics, and to explore how these pathways may be translated into precision medicine approaches. This review integrates molecular, microbial, and neuroimmune perspectives to propose a systems-level understanding of IBS pathophysiology and its implications for precision medicine. By integrating host-microbe interactions, dietary influences, and genetic predispositions, we highlight the mechanistic complexity underlying IBS and the potential for translating these insights into personalized strategies for symptom control and improved quality of life.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.